{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:57:11Z","timestamp":1790834231638,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010096","name":"Southern Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81302372"],"award-info":[{"award-number":["81302372"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.intimp.2021.108497","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T06:31:28Z","timestamp":1641450688000},"page":"108497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D\/NKG2DL activation pathway"],"prefix":"10.1016","volume":"104","author":[{"given":"Hui-yang","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-ying","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-qi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dei-zhi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-xian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2021.108497_b0005","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00277-020-03922-w","article-title":"Post-Remission Therapy of Adults Aged 60 and Older with Acute Myeloid Leukemia in First Complete Remission: Role of Treatment Intensity on the Outcome","volume":"99","author":"Bouchacourt","year":"2020","journal-title":"Annals of hematology"},{"issue":"2","key":"10.1016\/j.intimp.2021.108497_b0010","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.seminhematol.2019.02.002","article-title":"Shifting Paradigms in the Treatment of Older Adults with Aml","volume":"56","author":"LeBlanc","year":"2019","journal-title":"Semin Hematol"},{"issue":"2","key":"10.1016\/j.intimp.2021.108497_b0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-Based Therapies for Acute Myeloid Leukemia","volume":"32","author":"Guerra","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.intimp.2021.108497_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.562558","article-title":"Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions","volume":"10","author":"Samra","year":"2020","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.intimp.2021.108497_b0025","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3324\/haematol.2019.242826","article-title":"Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis","volume":"105","author":"Bewersdorf","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.intimp.2021.108497_b0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2021.108497_b0035","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical Experience with the Bcl2-Inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.intimp.2021.108497_b0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0165-5","article-title":"Superior Efficacy of Cotreatment with Bet Protein Inhibitor and Bcl2 or Mcl1 Inhibitor against Aml Blast Progenitor Cells","volume":"9","author":"Fiskus","year":"2019","journal-title":"Blood cancer journal"},{"issue":"4","key":"10.1016\/j.intimp.2021.108497_b0045","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax Combines Synergistically with Flt3 Inhibition to Effectively Target Leukemic Cells in Flt3-Itd+ Acute Myeloid Leukemia Models","volume":"106","author":"Raghuveer Singh Mali","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.intimp.2021.108497_b0050","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/hon.2794","article-title":"Combining T-Cell-Based Immunotherapy with Venetoclax Elicits Synergistic Cytotoxicity to B-Cell Lines in Vitro","volume":"38","author":"Murakami","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.intimp.2021.108497_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.651751","article-title":"Role of Polymorphisms of Nkg2d Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation","volume":"12","author":"Machuldova","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.intimp.2021.108497_b0060","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"Nk Cells for Cancer Immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.intimp.2021.108497_b0065","doi-asserted-by":"crossref","first-page":"111299","DOI":"10.1016\/j.biopha.2021.111299","article-title":"Targeting the Nkg2d\/Nkg2d-L Axis in Acute Myeloid Leukemia","volume":"137","author":"Wu","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"10.1016\/j.intimp.2021.108497_b0070","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.3390\/ijms20092057","article-title":"Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia","volume":"20","author":"Hattori","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.intimp.2021.108497_b0075","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.3389\/fimmu.2019.02357","article-title":"Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, Nk Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous Nk Cells","volume":"10","author":"Carlsten","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2021.108497_b0080","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-019-0956-8","article-title":"Natural Killer Group 2d Receptor and Its Ligands in Cancer Immune Escape","volume":"18","author":"Duan","year":"2019","journal-title":"Mol Cancer"},{"issue":"7768","key":"10.1016\/j.intimp.2021.108497_b0085","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","article-title":"Absence of Nkg2d Ligands Defines Leukaemia Stem Cells and Mediates Their Immune Evasion","volume":"572","author":"Paczulla","year":"2019","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.intimp.2021.108497_b0090","doi-asserted-by":"crossref","first-page":"11385","DOI":"10.3390\/ijms222111385","article-title":"The Biological Role and Therapeutic Potential of Nk Cells in Hematological and Solid Tumors","volume":"22","author":"Velichinskii","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.intimp.2021.108497_b0095","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.3389\/fimmu.2019.02557","article-title":"Post-Translational Mechanisms Regulating Nk Cell Activating Receptors and Their Ligands in Cancer: Potential Targets for Therapeutic Intervention","volume":"10","author":"Molfetta","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2021.108497_b0100","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-11-186","article-title":"Enhanced Interaction between Natural Killer Cells and Lung Cancer Cells: Involvement in Gefitinib-Mediated Immunoregulation","volume":"11","author":"He","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.intimp.2021.108497_b0105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/CJI.0000000000000168","article-title":"Sunitinib Induces Nk-Kappab-Dependent Nkg2d Ligand Expression in Nasopharyngeal Carcinoma and Hepatoma Cells","volume":"40","author":"Huang","year":"2017","journal-title":"J Immunother"},{"issue":"5","key":"10.1016\/j.intimp.2021.108497_b0110","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00432-010-0944-2","article-title":"Role of Sorafenib and Sunitinib in the Induction of Expressions of Nkg2d Ligands in Nasopharyngeal Carcinoma with High Expression of Abcg2","volume":"137","author":"Huang","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.intimp.2021.108497_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.712722","article-title":"Manipulating the Nkg2d Receptor-Ligand Axis Using Crispr: Novel Technologies for Improved Host Immunity","volume":"12","author":"Alves","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.intimp.2021.108497_b0120","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-17-3024","article-title":"Cotargeting Bcl-2 and Pi3k Induces Bax-Dependent Mitochondrial Apoptosis in Aml Cells","volume":"78","author":"Rahmani","year":"2018","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.intimp.2021.108497_b0125","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1038\/leu.2017.147","article-title":"Targeting Flt3 by Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.intimp.2021.108497_b0130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/gene.2014.58","article-title":"Methylation of Nkg2d Ligands Contributes to Immune System Evasion in Acute Myeloid Leukemia","volume":"16","author":"Baraga\u00f1o Raneros","year":"2015","journal-title":"Genes Immun"},{"key":"10.1016\/j.intimp.2021.108497_b0135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/978-1-62703-601-6_20","article-title":"Functional Nk Cell Cytotoxicity Assays against Virus Infected Cells","volume":"1064","author":"Aicheler","year":"2013","journal-title":"Methods Mol Biol"},{"issue":"2","key":"10.1016\/j.intimp.2021.108497_b0140","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbrc.2020.01.094","article-title":"Artemisinin Sensitizes Tumor Cells to Nk Cell-Mediated Cytolysis","volume":"524","author":"Lu","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.intimp.2021.108497_b0145","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/bs.mie.2019.05.020","article-title":"Cfse Dilution to Study Human T and Nk Cell Proliferation in Vitro","volume":"631","author":"Terren","year":"2020","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.intimp.2021.108497_b0150","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-020-00996-x","article-title":"Natural Killer Cell-Based Immunotherapy for Acute Myeloid Leukemia","volume":"13","author":"Xu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.intimp.2021.108497_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.695051","article-title":"Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia","volume":"12","author":"Limongello","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2021.108497_b0160","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbmt.2015.12.028","article-title":"Phase Ii Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation","volume":"22","author":"Shaffer","year":"2016","journal-title":"Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation"},{"issue":"8","key":"10.1016\/j.intimp.2021.108497_b0165","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1158\/1078-0432.CCR-15-1604","article-title":"Larger Size of Donor Alloreactive Nk Cell Repertoire Correlates with Better Response to Nk Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients","volume":"22","author":"Curti","year":"2016","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.intimp.2021.108497_b0170","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-3684-7_28","article-title":"Generation of Bikes and Trikes to Improve Nk Cell-Mediated Targeting of Tumor Cells","volume":"1441","author":"Felices","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"2","key":"10.1016\/j.intimp.2021.108497_b0175","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1084\/jem.20160869","article-title":"Cell Cycle Progression Dictates the Requirement for Bcl2 in Natural Killer Cell Survival","volume":"214","author":"Viant","year":"2017","journal-title":"J Exp Med"},{"issue":"19","key":"10.1016\/j.intimp.2021.108497_b0180","doi-asserted-by":"crossref","first-page":"10761","DOI":"10.3390\/ijms221910761","article-title":"Synergistic Effects of Venetoclax and Daratumumab on Antibody-Dependent Cell-Mediated Natural Killer Cytotoxicity in Multiple Myeloma","volume":"22","author":"Nakamura","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"17","key":"10.1016\/j.intimp.2021.108497_b0185","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/bloodadvances.2019000360","article-title":"Distinct Immune Composition in Lymph Node and Peripheral Blood of Cll Patients Is Reshaped During Venetoclax Treatment","volume":"3","author":"de Weerdt","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.intimp.2021.108497_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.659253","article-title":"Escape from Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia","volume":"11","author":"van Gils","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.intimp.2021.108497_b0195","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-Based Drug Screening Reveals Association between Venetoclax Response and Differentiation Stage in Acute Myeloid Leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.intimp.2021.108497_b0200","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.3390\/jcm9103090","article-title":"Absence of Bcl-2 Expression Identifies a Subgroup of Aml with Distinct Phenotypic, Molecular, and Clinical Characteristics","volume":"9","author":"haes","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.intimp.2021.108497_b0205","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00262-015-1665-9","article-title":"Nz28-Induced Inhibition of Hsf1, Sp1 and Nf-Kappab Triggers the Loss of the Natural Killer Cell-Activating Ligands Mica\/B on Human Tumor Cells","volume":"64","author":"Schilling","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.intimp.2021.108497_b0210","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.imlet.2020.06.014","article-title":"Cxc Chemokine Receptor 3 Antagonist Amg487 Shows Potent Anti-Arthritic Effects on Collagen-Induced Arthritis by Modifying B Cell Inflammatory Profile","volume":"225","author":"Bakheet","year":"2020","journal-title":"Immunology letters"},{"key":"10.1016\/j.intimp.2021.108497_b0215","doi-asserted-by":"crossref","first-page":"106494","DOI":"10.1016\/j.intimp.2020.106494","article-title":"Cxcr3 Antagonist Amg487 Inhibits Glucocorticoid-Induced Tumor Necrosis Factor-Receptor-Related Protein and Inflammatory Mediators in Cd45 Expressing Cells in Collagen-Induced Arthritis Mouse Model","volume":"84","author":"Bakheet","year":"2020","journal-title":"International immunopharmacology"},{"key":"10.1016\/j.intimp.2021.108497_b0220","doi-asserted-by":"crossref","first-page":"109395","DOI":"10.1016\/j.cellsig.2019.109395","article-title":"Cxcr3 Antagonist Amg487 Suppresses Rheumatoid Arthritis Pathogenesis and Progression by Shifting the Th17\/Treg Cell Balance","volume":"64","author":"Bakheet","year":"2019","journal-title":"Cell Signal"},{"issue":"7","key":"10.1016\/j.intimp.2021.108497_b0225","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3390\/molecules26071839","article-title":"Chemokine Receptor 5 Antagonism Causes Reduction in Joint Inflammation in a Collagen-Induced Arthritis Mouse Model","volume":"26","author":"Ansari","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.intimp.2021.108497_b0230","doi-asserted-by":"crossref","first-page":"982","DOI":"10.55563\/clinexprheumatol\/klc3h6","article-title":"Nkg2d Ligands in Inflammatory Joint Diseases: Analysis in Human Samples and Mouse Models","volume":"39","author":"Mariotte","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.intimp.2021.108497_b0235","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00262-012-1235-3","article-title":"Midkine Upregulates Mica\/B Expression in Human Gastric Cancer Cells and Decreases Natural Killer Cell Cytotoxicity","volume":"61","author":"Zhao","year":"2012","journal-title":"Cancer Immunol Immunother"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921011334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921011334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:32:01Z","timestamp":1761586321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921011334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":47,"alternative-id":["S1567576921011334"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108497","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D\/NKG2DL activation pathway","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108497"}}